Rebranding PCOS to Better Reflect Systemic Impact

Health specialists in Jersey argue that renaming a metabolic disorder affecting over 170 million women worldwide is a necessary step to accurately characterize it as a systemic issue rather than merely an ovarian one. Consequently, Polycystic Ovary Syndrome (PCOS) has been officially renamed to Polyendocrine Metabolic Ovarian Syndrome (PMOS). The International PCOS Network stated that this rebranding, which took effect on May 12, aims to enhance public comprehension and facilitate more effective diagnostic and treatment pathways.

Jessica Pinel, a nutritionist and chair of PCOS Jersey, emphasized that the previous terminology was restrictive. Diagnosed three years ago after spending more than £3,000 on treatment, Pinel noted that the old name suggested the condition was confined to the ovaries, whereas it is in fact a full-body affliction.

According to the NHS, individuals with PMOS/PCOS often experience elevated male hormone levels, irregular menstruation, and weight gain. Pinel, who supports numerous women navigating the condition, highlighted the vast diversity of symptoms that significantly disrupt daily life. These manifestations can include fatigue, unwanted hair growth, acne, "brain fog," irregular cycles, and infertility.

"It is that full-body condition with a range of different symptoms," Pinel explained. "Hopefully, [the name change] allows more women to get support and treatment for that range of different symptoms because the condition affects us in unique ways."

Pinel stressed the critical need for better education to help women identify the condition and to support those already diagnosed. She warned against relying on social media platforms like TikTok, Instagram, and Facebook for medical information, citing the prevalence of misinformation. This concern is backed by a 2024 BBC investigation that revealed influencers peddling fraudulent cures for PCOS. Consequently, Pinel advised individuals suspecting they have the condition to pursue professional medical guidance.

Regarding diagnosis, she encouraged patients to advocate for themselves. "In terms of diagnosis, you are always entitled to a second opinion," she said. "I wasn't diagnosed the first few times. I had those exploratory tests, so I sought out a secondary opinion because I know my body. If you feel like you're not being seen or heard, then please go and seek that second opinion because you deserve it."

The government has indicated that a women’s health strategy, mandated by the Government Plan, is scheduled for release later this year.

Dr. Jessica Langtree-Marsh, a Jersey GP, described PCOS/PMOS as a condition that is both significantly under-researched and widely misunderstood. She argued that early diagnosis and education are vital for ensuring individuals receive the correct care. Dr. Langtree-Marsh criticized the common clinical approach of dismissing the condition until pregnancy is desired, stating, "Actually, we need to look at this as a lifespan condition."

She expressed hope that the new nomenclature would encourage broader treatment strategies beyond the traditional reliance on contraceptive pills, potentially incorporating metabolic medications to address the underlying issues.

The condition was originally identified 70 years ago by surgeons Dr. Irving Stein and Dr. Michael Leventhal. While operating on women with amenorrhea, they observed specific ovarian characteristics and initially named the disorder Stein-Leventhal Syndrome before it was rebranded as PCOS. Dr. Langtree-Marsh noted that while the original name acknowledged ovarian involvement, it failed to capture the systemic nature of the disease.

"So the rebranded PMOS is trying to appreciate that it affects women more generally rather than just the ovaries, so that it's a whole body condition," she said. Although she admitted the new name is not particularly catchy, she welcomed the shift in definition away from a purely ovarian focus.

Source: BBC News Generated at: 2026-05-26 05:27:03 UTC